- Home
- PHAR vs LENZ Comparison
PHAR vs LENZ Comparison
Compare PHAR & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- LENZ
- Stock Information
- Founded
- PHAR 1988
- LENZ 2019
- Country
- PHAR Netherlands
- LENZ United States
- Employees
- PHAR N/A
- LENZ N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- PHAR Health Care
- LENZ Health Care
- Exchange
- PHAR Nasdaq
- LENZ Nasdaq
- Market Cap
- PHAR 798.2M
- LENZ 886.0M
- IPO Year
- PHAR N/A
- LENZ 2021
- Fundamental
- Price
- PHAR $13.70
- LENZ $40.00
- Analyst Decision
- PHAR Strong Buy
- LENZ Strong Buy
- Analyst Count
- PHAR 3
- LENZ 4
- Target Price
- PHAR $30.00
- LENZ $49.75
- AVG Volume (30 Days)
- PHAR 12.8K
- LENZ 722.0K
- Earning Date
- PHAR 07-31-2025
- LENZ 07-30-2025
- Dividend Yield
- PHAR N/A
- LENZ N/A
- EPS Growth
- PHAR N/A
- LENZ N/A
- EPS
- PHAR N/A
- LENZ N/A
- Revenue
- PHAR $339,836,000.00
- LENZ $5,000,000.00
- Revenue This Year
- PHAR $12.88
- LENZ N/A
- Revenue Next Year
- PHAR $8.54
- LENZ $556.26
- P/E Ratio
- PHAR N/A
- LENZ N/A
- Revenue Growth
- PHAR 22.44
- LENZ N/A
- 52 Week Low
- PHAR $6.73
- LENZ $16.54
- 52 Week High
- PHAR $17.08
- LENZ $41.70
- Technical
- Relative Strength Index (RSI)
- PHAR 67.43
- LENZ 63.32
- Support Level
- PHAR $12.13
- LENZ $36.30
- Resistance Level
- PHAR $12.76
- LENZ $41.70
- Average True Range (ATR)
- PHAR 0.89
- LENZ 2.89
- MACD
- PHAR 0.13
- LENZ 0.45
- Stochastic Oscillator
- PHAR 44.41
- LENZ 86.48
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.